↓ Skip to main content

Prospective evaluation of 18F-FACBC PET/CT and PET/MRI versus multiparametric MRI in intermediate- to high-risk prostate cancer patients (FLUCIPRO trial)

Overview of attention for article published in European Journal of Nuclear Medicine and Molecular Imaging, November 2017
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (67th percentile)
  • Good Attention Score compared to outputs of the same age and source (76th percentile)

Mentioned by

twitter
7 X users

Citations

dimensions_citation
68 Dimensions

Readers on

mendeley
71 Mendeley
Title
Prospective evaluation of 18F-FACBC PET/CT and PET/MRI versus multiparametric MRI in intermediate- to high-risk prostate cancer patients (FLUCIPRO trial)
Published in
European Journal of Nuclear Medicine and Molecular Imaging, November 2017
DOI 10.1007/s00259-017-3875-1
Pubmed ID
Authors

Ivan Jambor, Anna Kuisma, Esa Kähkönen, Jukka Kemppainen, Harri Merisaari, Olli Eskola, Jarmo Teuho, Ileana Montoya Perez, Marko Pesola, Hannu J. Aronen, Peter J. Boström, Pekka Taimen, Heikki Minn

Abstract

The purpose of this study was to evaluate (18)F-FACBC PET/CT, PET/MRI, and multiparametric MRI (mpMRI) in detection of primary prostate cancer (PCa). Twenty-six men with histologically confirmed PCa underwent PET/CT immediately after injection of 369 ± 10 MBq (18)F-FACBC (fluciclovine) followed by PET/MRI started 55 ± 7 min from injection. Maximum standardized uptake values (SUVmax) were measured for both hybrid PET acquisitions. A separate mpMRI was acquired within a week of the PET scans. Logan plots were used to calculate volume of distribution (VT). The presence of PCa was estimated in 12 regions with radical prostatectomy findings as ground truth. For each imaging modality, area under the curve (AUC) for detection of PCa was determined to predict diagnostic performance. The clinical trial registration number is NCT02002455. In the visual analysis, 164/312 (53%) regions contained PCa, and 41 tumor foci were identified. PET/CT demonstrated the highest sensitivity at 87% while its specificity was low at 56%. The AUC of both PET/MRI and mpMRI significantly (p < 0.01) outperformed that of PET/CT while no differences were detected between PET/MRI and mpMRI. SUVmax and VT of Gleason score (GS) >3 + 4 tumors were significantly (p < 0.05) higher than those for GS 3 + 3 and benign hyperplasia. A total of 442 lymph nodes were evaluable for staging, and PET/CT and PET/MRI demonstrated true-positive findings in only 1/7 patients with metastatic lymph nodes. Quantitative (18)F-FACBC imaging significantly correlated with GS but failed to outperform MRI in lesion detection. (18)F-FACBC may assist in targeted biopsies in the setting of hybrid imaging with MRI.

X Demographics

X Demographics

The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 71 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 71 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 19 27%
Other 9 13%
Student > Bachelor 5 7%
Student > Ph. D. Student 5 7%
Student > Master 4 6%
Other 9 13%
Unknown 20 28%
Readers by discipline Count As %
Medicine and Dentistry 20 28%
Nursing and Health Professions 5 7%
Computer Science 4 6%
Physics and Astronomy 3 4%
Pharmacology, Toxicology and Pharmaceutical Science 2 3%
Other 8 11%
Unknown 29 41%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 November 2017.
All research outputs
#6,567,072
of 23,806,312 outputs
Outputs from European Journal of Nuclear Medicine and Molecular Imaging
#809
of 3,083 outputs
Outputs of similar age
#94,270
of 296,160 outputs
Outputs of similar age from European Journal of Nuclear Medicine and Molecular Imaging
#10
of 43 outputs
Altmetric has tracked 23,806,312 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 3,083 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.1. This one has gotten more attention than average, scoring higher than 73% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 296,160 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.
We're also able to compare this research output to 43 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 76% of its contemporaries.